Small Interfering RNA (siRNA) Therapeutics Market by Type and Application- Global Industry Analysis & Forecast to 2027
Published On : December 2020 Pages : 157 Category: Medical Devices Report Code : HC1214084
Small Interfering RNA (siRNA) Therapeutics Market by Type (Nanoparticle Based Systemic Therapy,Liposome Based Systemic Therapy)Application (Pharmaceutical and Biotechnology Companies,Hospital,Academic Institutions,Research Institutions)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Small Interfering RNA (siRNA) Therapeutics Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Small interfering RNA (siRNA) is a sort of hereditary medication, which can possibly quietness or thump down any over-communicated quality in an illness. It is likewise called short meddling RNA. These RNAs are generally used to assess the particular commitment of qualities to an assortment of cell aggregates including insulin signaling, apoptosis, cytokinesis, and cell differentiation.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Horizon Discovery
- GE
- Genecon Biotechnologies
- Thermo Scientific
- Arbutus Biopharma
- AInylam Pharmaceuticals
- OPKO Health
- OPKO Health
- Arrowhead Research
- Silent Therapeutics
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Small Interfering RNA (siRNA) Therapeutics Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o Nanoparticle Based Systemic Therapy
o Liposome Based Systemic Therapy
· Small Interfering RNA (siRNA) Therapeutics Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Pharmaceutical and Biotechnology Companies
o Hospital
o Academic Institutions
· Small Interfering RNA (siRNA) Therapeutics Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Horizon Discovery
o GE
o Genecon Biotechnologies
o Thermo Scientific
o Arbutus Biopharma
o AInylam Pharmaceuticals
o OPKO Health
o Sanofi Genzyme
o Arrowhead Research
o Silent Therapeutics
· Small Interfering RNA (siRNA) Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Small Interfering RNA (siRNA) Therapeutics Market, By Country
o U.S. Small Interfering RNA (siRNA) Therapeutics Market
o Canada Small Interfering RNA (siRNA) Therapeutics Market
o Mexico Small Interfering RNA (siRNA) Therapeutics Market
o Europe
§ Europe Small Interfering RNA (siRNA) Therapeutics Market, By Country
· Germany Small Interfering RNA (siRNA) Therapeutics Market
o UK Small Interfering RNA (siRNA) Therapeutics Market
o France Small Interfering RNA (siRNA) Therapeutics Market
o RussiaSmall Interfering RNA (siRNA) Therapeutics Market
o Italy Small Interfering RNA (siRNA) Therapeutics Market
o Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market
o Asia-Pacific
§ Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market, By Country
o ChinaSmall Interfering RNA (siRNA) Therapeutics Market
o Japan Small Interfering RNA (siRNA) Therapeutics Market
o South KoreaSmall Interfering RNA (siRNA) Therapeutics Market
o India Small Interfering RNA (siRNA) Therapeutics Market
o Southeast AsiaSmall Interfering RNA (siRNA) Therapeutics Market
o Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market
o South America
§ South AmericaSmall Interfering RNA (siRNA) Therapeutics Market
o Brazil Small Interfering RNA (siRNA) Therapeutics Market
o ArgentinaSmall Interfering RNA (siRNA) Therapeutics Market
o ColumbiaSmall Interfering RNA (siRNA) Therapeutics Market
o Rest of South America Small Interfering RNA (siRNA) Therapeutics Market
o Middle East and Africa
§ Middle East and AfricaSmall Interfering RNA (siRNA) Therapeutics Market
o Saudi ArabiaSmall Interfering RNA (siRNA) Therapeutics Market
o UAESmall Interfering RNA (siRNA) Therapeutics Market
o EgyptSmall Interfering RNA (siRNA) Therapeutics Market
o NigeriaSmall Interfering RNA (siRNA) Therapeutics Market
o South Africa Small Interfering RNA (siRNA) Therapeutics Market
o Rest of MEA Small Interfering RNA (siRNA) Therapeutics Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Small Interfering RNA (siRNA) Therapeutics Market, By Type
5.1. Introduction
5.2. Global Small Interfering RNA (siRNA) Therapeutics Revenue and Market Share by Type (2017-2021)
5.2.1. Global Small Interfering RNA (siRNA) Therapeutics Revenue and Revenue Share by Type (2017-2021)
5.3. Nanoparticle Based Systemic Therapy
5.3.1. Global Nanoparticle Based Systemic Therapy Revenue and Growth Rate (2017-2021)
5.4. Liposome Based Systemic Therapy
5.4.1. Global Liposome Based Systemic Therapy Revenue and Growth Rate (2017-2021)
6. Small Interfering RNA (siRNA) Therapeutics Market, By Application
6.1. Introduction
6.2. Global Small Interfering RNA (siRNA) Therapeutics Revenue and Market Share by Application (2017-2021)
6.2.1. Global Small Interfering RNA (siRNA) Therapeutics Revenue and Revenue Share by Application (2017-2021)
6.3. Pharmaceutical and Biotechnology Companies
6.3.1. Global Pharmaceutical and Biotechnology Companies Revenue and Growth Rate (2017-2021)
6.4. Hospital
6.4.1. Global Hospital Revenue and Growth Rate (2017-2021)
6.5. Academic Institutions
6.5.1. Global Academic Institutions Revenue and Growth Rate (2017-2021)
6.6. Research Institutions
6.6.1. Global Research Institutions Revenue and Growth Rate (2017-2021)
7. Small Interfering RNA (siRNA) Therapeutics Market, By Region
7.1. Introduction
7.2. Global Small Interfering RNA (siRNA) Therapeutics Revenue and Market Share by Regions
7.2.1. Global Small Interfering RNA (siRNA) Therapeutics Revenue by Regions (2017-2021)
7.3. North America Small Interfering RNA (siRNA) Therapeutics by Countries
7.3.1. North America Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2021)
7.3.2. North America Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Small Interfering RNA (siRNA) Therapeutics by Countries
7.4.1. Europe Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2021)
7.4.2. Europe Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Small Interfering RNA (siRNA) Therapeutics by Countries
7.5.1. Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Small Interfering RNA (siRNA) Therapeutics by Countries
7.6.1. South America Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2021)
7.6.2. South America Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Small Interfering RNA (siRNA) Therapeutics by Countries
7.7.1. Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Horizon Discovery
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. GE
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Genecon Biotechnologies
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Thermo Scientific
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Arbutus Biopharma
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. AInylam Pharmaceuticals
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. OPKO Health
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. OPKO Health
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Arrowhead Research
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Silent Therapeutics
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.1. Global Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Small Interfering RNA (siRNA) Therapeutics Market Forecast by Regions (2022-2027)
9.2.1. North America Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.1.1. United States Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.1.2. Canada Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.1.3. Mexico Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2. Europe Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2.1. Germany Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2.2. France Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2.3. UK Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2.4. Russia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2.5. Italy Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3. Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3.1. China Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3.2. Japan Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3.3. Korea Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3.4. India Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.4. South America Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.4.1. Brazil Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.4.2. Argentina Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.4.3. Columbia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.4.4. Rest of South America Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5. Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.3. Egypt Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.4. Nigeria Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.5. South Africa Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.6. Turkey Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecast (2022-2027)
9.3. Small Interfering RNA (siRNA) Therapeutics Market Forecast by Type (2022-2027)
9.3.1. Small Interfering RNA (siRNA) Therapeutics Forecast by Type (2022-2027)
9.3.2. Small Interfering RNA (siRNA) Therapeutics Market Share Forecast by Type (2022-2027)
9.4. Small Interfering RNA (siRNA) Therapeutics Market Forecast by Application (2022-2027)
9.4.1. Small Interfering RNA (siRNA) Therapeutics Forecast by Application (2022-2027)
9.4.2. Small Interfering RNA (siRNA) Therapeutics Market Share Forecast by Application (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Small Interfering RNA (siRNA) Therapeutics Revenue and Revenue Share by Type (2017-2019)
Figure Global Nanoparticle Based Systemic Therapy Revenue and Growth Rate (2017-2019)
Figure Global Liposome Based Systemic Therapy Revenue and Growth Rate (2017-2019)
Table Global Small Interfering RNA (siRNA) Therapeutics Revenue and Revenue Share by Application (2017-2019)
Figure Global Pharmaceutical and Biotechnology Companies Revenue and Growth Rate (2017-2019)
Figure Global Hospital Revenue and Growth Rate (2017-2019)
Figure Global Academic Institutions Revenue and Growth Rate (2017-2019)
Figure Global Research Institutions Revenue and Growth Rate (2017-2019)
Table Global Small Interfering RNA (siRNA) Therapeutics Revenue by Regions (2017-2019)
Figure North America Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure North America Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2019)
Figure North America Small Interfering RNA (siRNA) Therapeutics by Countries (2017-2019)
Figure North America Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure United States Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure United States Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Canada Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Mexico Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Europe Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2019)
Figure Europe Small Interfering RNA (siRNA) Therapeutics by Countries (2017-2019)
Figure Europe Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure Germany Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Germany Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure France Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure UK Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Russia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Italy Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Rest of Europe Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Small Interfering RNA (siRNA) Therapeutics by Countries (2017-2019)
Figure Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure China Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure China Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Japan Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Korea Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure India Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Southeast Asia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure South America Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2019)
Figure South America Small Interfering RNA (siRNA) Therapeutics by Countries (2017-2019)
Figure South America Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Brazil Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Argentina Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Columbia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Rest of South America Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Small Interfering RNA (siRNA) Therapeutics by Countries (2017-2019)
Figure Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure United Arab Emirates Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Egypt Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Nigeria Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure South Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Turkey Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Table Horizon Discovery Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table GE Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table Genecon Biotechnologies Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table Thermo Scientific Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table Arbutus Biopharma Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table AInylam Pharmaceuticals Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table OPKO Health Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table OPKO Health Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table Arrowhead Research Small Interfering RNA (siRNA) Therapeutics Financial Overview
Table Silent Therapeutics Small Interfering RNA (siRNA) Therapeutics Financial Overview
Figure Global Small Interfering RNA (siRNA) Therapeutics Revenue (Millions USD) and Growth Rate (2019-2027)
Table Small Interfering RNA (siRNA) Therapeutics Market Forecast by Regions (2019-2027)
Figure North America Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure United States Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Canada Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Mexico Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Europe Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Germany Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure France Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure UK Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Russia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Italy Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure China Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Japan Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Korea Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure India Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Southeast Asia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure South America Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Brazil Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Argentina Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Columbia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Rest of South America Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure United Arab Emirates Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Egypt Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Nigeria Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure South Africa Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Turkey Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecast (2019-2027)
Figure Global Small Interfering RNA (siRNA) Therapeutics Forecast by Type (2019-2027)
Figure Global Small Interfering RNA (siRNA) Therapeutics Market Share Forecast by Type (2019-2027)
Figure Global Small Interfering RNA (siRNA) Therapeutics Forecast by Type (2019-2027)
Figure Global Small Interfering RNA (siRNA) Therapeutics Forecast by Application (2019-2027)
Figure Global Small Interfering RNA (siRNA) Therapeutics Market Share Forecast by Application (2019-2027)
Figure Global Small Interfering RNA (siRNA) Therapeutics Forecast by Application (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|